Exhibit 107

Calculation of Filing Fee Tables

 

Form S-1

(Form Type)

 

MAIA BIOTECHNOLOGY, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered Securities

 

 

 

Security

Type

 

Security Class Title

 

Fee

Calculation

or Carry

Forward

Rule

 

Amount

Registered

 

 

Proposed

Maximum

Offering

Price Per

Unit

 

 

Maximum

Aggregate

Offering

Price(1) (2)

 

 

Fee Rate

 

 

Amount of

Registration

Fee

 

Fees to be Paid

 

Equity

 

Common shares, $0.0001 par value per share(2)

 

Rule 457(o)

 

 

 

 

 

$

 

 

 

$

15,000,000

 

 

 

$0.0000927

 

 

 

1,390.50

 

 

 

Equity

 

Representative warrants(3)

 

Rule 457(g)

 

 

 

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

(4)

Fees to  be Paid

 

Equity

 

Common shares issuable upon the exercise of the Representative’s warrants(5)

 

Rule 457(o)

 

 

 

 

 

$

 

 

 

 

 

 

 

 

$0.0000927

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Offering Amounts

 

 

 

 

 

 

 

 

 

 

 

$

15,000,000

 

 

 

 

 

 

$

1,390.50

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Fees Previously Paid

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Fee Offset

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Fee Due

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

$

1,390.50

 

 

(1) Includes shares of common stock of MAIA Biotechnology, Inc. (the “Company”), which the underwriters have the right to purchase to cover over-allotments. See “Underwriting.”

 

(2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. The Company has not had any third-party sales and there is currently no market for the Company’s common shares.

 

(3) Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price of the securities registered hereunder to be sold by the registrant and includes the offering price of shares of common stock that the underwriters have an option to purchase to cover over-allotments, if any.

 

(4) No fee required pursuant to Rule 457(g).

 

(5) We have agreed to issue to the representative of the underwriters (the “Representative”), upon the closing of this offering, warrants to purchase up to an aggregate number of shares of our common stock (the “Representative’s Warrants”) in an aggregate equal to five percent (5%) of the aggregate number of shares of common stock to be issued and sold in this offering, but excluding any shares sold upon exercise of the underwriters’ over-allotment option) (the “Representative’s Warrants”). The Representative’s Warrants are exercisable at a per share price equal to 125% of the public offering price per share of the shares of common stock sold in this offering (excluding the over-allotment option). As estimated solely for the purpose of recalculating the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the Representative’s Warrants is $[ ], which is equal to 125% of $[ ] (5.0% of $[ ]). See “Underwriting”.